Clinical utility of colon capsule endoscopy: a moving target?

Abstract

The purpose of this article is to provide an overview of white light colon capsule endoscopy’s current clinical application, concentrating on its most recent developments. Second-generation colon capsule endoscopy (CCE2) is approved by the FDA for use as an adjunctive test in patients with incomplete colonoscopy and within Europe in patients at average risk, those with incomplete colonoscopies or those unwilling to undergo conventional colonoscopies. Since the publication of European Society of GI Endoscopy guidelines on the use of CCE, there has been a significant increase in comparative studies on the diagnostic yield of CCE. This paper discusses CCE2 in further detail. It explains newly developed colon capsule system and the current status on the use of CCE, it also provides a comprehensive summary of systematic reviews on the implementation of CCE in colorectal cancer screening from a methodological perspective. Patients with ulcerative colitis can benefit from CCE2 in terms of assessing mucosal inflammation. As part of this review, performance of CCE2 for assessing disease severity in ulcerative colitis is compared with colonoscopy. Finally, an assessment if CCE can become a cost-effective clinical service overall.

Rationalizing polyp matching criteria in colon capsule endoscopy: an international expert consensus through RAND (modified DELPHI) process

“…The stages of integrating artificial intelligence (AI) into the CCE process detailed by Robertson et al propose a scenario where AI could initially replace the pre-reading process and eventually take on the responsibility for analysing the entire CCE video prior to the clinician’s validation and reporting. 12 – 14 This proposal comprises of different stages. It suggested that the clinician would be presented with all the polyps’ images without a comprehensive review of the whole CCE video.…”